Skip to main content

Market Overview

AnaptysBio's Imsidolimab Fails To Separate From Placebo In Skin Blistering Disorder Study


AnaptysBio Inc (NASDAQ: ANAB) reports disappointing top-line data from its Phase 2 (POPLAR) trial of imsidolimab for palmoplantar pustulosis (PPP).

  • The study failed to meet its primary endpoint of improvement on disease severity index from baseline at week 16, compared to placebo.
  • PPP is an autoimmune disorder characterized by blister-like sores on the palms of hands and feet' soles.
  • Improvement in disease severity index at week 16 was 6.1 for imsidolimab-treated patients, compared to 6.3 in the placebo group.
  • The mean change in disease severity from baseline was 5.78 or 38% improvement in the Imsidolimab arm, versus 6.78 or 33% improvement on the placebo.
  • Nine patients achieved 50% improvement, and four patients achieved 75% improvement in the imsidolimab arm at week 16, compared to 12 and 3 responders in the placebo arm, respectively.
  • Five imsidolimab-treated patients achieved almost clear skin at week 16 relative to 3 on placebo.
  • Further development in PPP is not currently anticipated, but the company will continue developing imsidolimab in five other immuno-dermatological indications.
  • Phase 3 study in generalized pustular psoriasis will start during mid-2021.
  • Imsidolimab was generally well-tolerated with a similar frequency of adverse events between treatment groups, and no severe or serious adverse events were observed in the imsidolimab arm. 
  • Price Action: ANAB shares trading has been halted, set to resume at 8:30 am EST.

Related Articles (ANAB)

View Comments and Join the Discussion!

Posted-In: palmoplantar pustulosis Phase 2Biotech News Health Care Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at